Found 8 clinical trials
Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma (PRECISION-NEC)
PRECISION-NEC is a single-center, open-label, pilot feasibility study of molecularly defined subtypes of metastatic high-grade neuroendocrine carcinoma (HG-NEC). The hypothesis is that HG-NEC (excluding small cell carcinoma) can be segregated based on mutational analysis and that next generation sequencing (NGS)-based assignment of therapy is feasible and will potentially improve the …
- 103 views
- 23 Mar, 2022
- 1 location
Effect of CGA for Frail Elderly Patients Operated for Colorectal Cancer - The CRC Frailty-study
This multicentre randomized controlled trial aims to investigate whether an individualized comprehensive geriatric assessment (CGA) and care will improve postoperative results in frail elderly patients undergoing surgery for colorectal cancer. The study will take place in departments applying the ERAS-concept which is considered gold standard in colorectal surgery.
- 0 views
- 17 Oct, 2021
- 2 locations
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
metanephrines, catecholamines and magnitude of reduction in serum chromogranin A, evaluated every two months while enrolled on study.
- 0 views
- 24 Nov, 2021
- 2 locations
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
The purpose of this study is find out if we can use simple tests (biomarkers) to tell us if a specific child would benefit most from CBT or from the low FODMAPs diet.
- 3 views
- 05 Feb, 2022
- 2 locations
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body and cannot be removed by surgery. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of …
- 0 views
- 24 Jan, 2022
- 1 location
CapTem Plus Radioembolization for NET Liver Metastases
Grade 2 neuroendocrine tumors have an intermediate rate of progression following embolotherapy of liver metastases. The combination of capecitabine and temozolomide has been shown to be an active regimen in this disease. Both drugs are radiosensitizers, and in a safety and feasibility study were combined with yttrium-90 radioembolization with acceptable …
- 0 views
- 10 Oct, 2021
- 1 location
Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy
This is a pilot study to test a hypothesis that a greater increase in serum chromogranin A (CgA) after a definitive radiotherapy (RT) with or without androgen deprivation therapy (ADT) is
- 8 views
- 22 Mar, 2022
- 1 location
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.
- 0 views
- 27 Jan, 2021
- 1 location